1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.

BACKGROUND: Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) has become a gold standard for people with HIV (PLWHIV) with high efficacy and safety rates in long-term data of pivotal clinical trials. However, data regarding immune status restoration in real-life c...

Descripción completa

Detalles Bibliográficos
Autores principales: Estévez, Samuel, Buzón, Luis, Pousada, Guillermo, Tomé, Roberto Pedrero, Galera, Carlos, Sanz, Jose, Santos, Ignacio, Dueñas, Carlos, Cabello, Noemí, Martín, Cristina, Galindo, María José, Garcinuño, María Ángeles, Hernández, Cristina, Lebón, Gabriela, Fernández, Beatriz, Troya, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678094/
http://dx.doi.org/10.1093/ofid/ofad500.1406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678094/
http://dx.doi.org/10.1093/ofid/ofad500.1406

Ejemplares similares